Cell Easy Appoints CDMO Expert Dr. Sebastien Ribault as Independent Board Director, to Accelerate Its Rapid Growth
11.5.2023 19:00:00 EEST | Business Wire | Press release
Cell-Easy SAS (“Cell-Easy”), a rapidly growing Contract Development and Manufacturing Organization (“CDMO”) that specializes in cell therapy, has appointed Dr. Sebastien Ribault, PhD, to its board of directors, to further accelerate its growth.
Cell-Easy is a leading contract development and manufacturing organization (CDMO) with a strong foothold in Good Manufacturing Practice (GMP) manufacturing services for immune cells (T, NK cells) and adult stem cells (MSCs, iPSCs). Since 2020, the company keeps expanding into genetically modified cells such as CAR-T and CAR-NK, while also broadening its service offerings of development and analytical services. To further accelerate its expansion plans and drive leadership in the immune cell therapy market, Cell-Easy is pleased to announce the appointment of Sebastien Ribault, PhD, to its board of directors.
Sebastien brings nearly three decades of executive leadership in the CDMO and biotechnology industries, including successful experience in end-to-end CDMO expansion. He began his career in the biotech field, at the gene specialist biotech Transgene, before moving to the instrumentation and CDMO industry. Most recently, Sebastien was Vice President & Head of Biologics and Viral Vector CDMO at Merck Life Science, where he demonstrated expertise in rapidly growing business units. Currently, Sebastien is the Chief Commercial Officer at Oxford Biomedica, a leading viral vector specialist, which is notably used in the generation of CAR-T and CAR-NK cell products.
Guillaume Costecalde, Co-Founder and President of Cell-Easy, said, “As we continue to scale our organization to meet the growing demand from clients, we are excited to welcome Sebastien to the team. With his proven track record in leading rapidly expanding CDMOs, he will provide strategic guidance to help Cell-Easy achieve market-leading status.”
Sebastien Ribault added, “I am delighted to join Cell-Easy’s Board of Directors at this exciting time for the company. Cell-Easy has already built an amazing team and successfully delivered on its core business in record time. I am excited to contribute to the company's journey as it continues to expand its services in cell therapy CDMO, with a focus on genetically modified cells and analytical services, building on its strong foundation and industry-leading expertise.”
With its focus on expanding its range of services and its experienced leadership team, Cell-Easy is well-positioned to continue its growth and success as a trusted partner for biotech and pharma companies looking to develop and manufacture innovative cell therapies.
About Cell-Easy
Cell-Easy takes pride in its proficiency in GMP manufacturing coupled with robust quality assurance and regulatory support to ensure successful process completion. Cell-Easy provides a range of services, in the manufacturing of qualified cell therapy products (T-cells, NK-cells, MSCs, iPSCs) and genetically modified cells (Car-T, CAR-NK) along with a broadened service catalogue of development and analytical services. Its relatively small team size enables it to adapt to the specific needs and preferences of clients.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005389/en/
Contact information
Media and Investor Contacts:
Emercell, Dr. Patrick Henno, President, patrick.henno@emercell.com, (+33)-6-14-77-39-21
Cell-Easy, Dr. Guillaume Lay, Business Development, Guillaume.lay@cell-easy.com, (+33)-6 15 18 13 13
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom